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Aims. Diabetes is considered a state of increased oxidative stress. This study evaluates blood concentrations of selected markers
of antioxidant defense in patients with type 2 diabetes.Methods. The study included 80 type 2 diabetes patients and 79 apparently
healthy controls. Measured markers included ferric reducing ability of plasma (FRAP), reduced glutathione (GSH), glutathione
peroxidase (GPx), glutathione reductase (GR), 𝛾-glutamyltransferase (GGT) and uric acid serum, and plasma and/or hemolysate
levels. Results. FRAP, uric acid, CRP, and GGT levels were significantly higher in patients with diabetes. Plasma and hemolysate GR
was significantly higher whereas GPx activity was significantly lower in patients with diabetes.There were no significant differences
in antioxidant defensemarkers between patients with andwithout chronic diabetes complications. Fasting serum glucose correlated
with plasma GPx, plasma and hemolysate GR, FRAP, and serum GGT, and HbA1c correlated with serum GGT. Only FRAP and
serum uric acid were significantly higher in obese (BMI > 30 kg/m2) patients with diabetes than in nonobese patients. Conclusions.
Some components of antioxidant defense such as GR, uric acid, and GGT are increased in patients with type 2 diabetes. However,
the whole system cannot compensate for an enhanced production of ROS as reflected by the trend toward decreased erythrocytes
GSH.
1. Introduction
Persistent hyperglycemia secondary to insulin resistance and
diminished insulin secretion in type 2 diabetes leads to
progressing organ injuries known as late or chronic diabetes
complications. It is believed that one of the underlying causes
of microvascular and macrovascular diabetes complications
is oxidative stress [1].
There are several suggested mechanisms linking hyper-
glycemia with increased production of reactive oxygen
species (ROS). These mechanisms include increased mito-
chondrial synthesis of superoxide anion radical (O
2
−) [2],
activation of the NF-𝜅B signaling pathway leading to inflam-
matory reaction and increased ROS production in phago-
cytes [3], increased glucose flux through the polyol pathway,
and formation of the advanced glycation end products (AGE)
enhancing oxidative stress [4].
In general, oxidative stress is caused by an imbalance
between ROS generation and antioxidant defense mecha-
nisms eliminating the superoxide anion radical and similar
compounds. Antioxidant defense system consists of a series
of specific enzymes, metal binding proteins, and a number
of low molecular weight antioxidants such as ascorbate,
cysteine, glutathione, and urate. Some elements of this system
are measured in blood as markers of antioxidant defense.
Diabetes is considered a state of increased oxidative stress
but the published data referring to impairment of antioxidant
defense in diabetic patients are contradictory [5, 6].
The aim of this study was to evaluate blood concentra-
tions of selected markers of antioxidant defense in patients
with type 2 diabetes and to assess the relationship between
antioxidant defense and glycemic control and the presence of
diabetes complications.
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Table 1: Demographic and biochemical characteristics of studied
patients with type 2 diabetes and controls.
Parameter Type 2 diabetes
𝑛 = 80
Control group
𝑛 = 79
Age [years] 59.5 ± 11.6 55.2 ± 11
Gender
Women 40 [50] 40 [51]
Men 40 [50] 39 [49]
Diabetes duration [years] 8.5 (4.0–12) —
BMI 31.54 ± 5.73 29.26 ± 8.43
Hypertension 77 [88.7] —
Obesity (BMI > 30 kg/m2) 44 [55] 32 [41]
No complications 38 [47.5%] —
Complications 42 [52.5%] —
Glucose [mmol/L] 6.75 (5.25–9.35) 4.4 (4.0–4.9)
HbA1c [%]
[mmol/mol]
8.5 (7.25–10.0)
69 (56–86) —
Creatinine [𝜇mol/L] 66.8 (58.2–82.0) —
e-GFR (MDRD)
[mL/min/1.73m2] 94.8 (75–116.4) —
TCH [mmol/L] 4.38 (3.82–5.27) 5.06 (4.09–5.9)
LDL [mmol/L] 2.21 (1.81–3.15) 2.94 (2.22–3.75)
HDL [mmol/L] 0.82 (0.71–1.00) 1.29 (1.06–1.24)
TG [mmol/L] 2.55 (1.74–3.75) 1.47 (1.08–1.87)
Albuminuria [mg/L] 2.51 (0.0–8.03) —
Data are expressed as mean ± SD, median and interquartile range, or
percentage of frequency [%], as appropriate.
2. Materials and Methods
The study included 80 patients with type 2 diabetes—40
females and 40 males, aged from 30 to 80 years (mean
59.5 ± 11.5), hospitalized in the Department of Metabolic
Diseases, University Hospital, Krakow, Poland. Mean disease
duration from diagnosis was 8.5 years (4–12). In 77 (88.7%)
patients arterial hypertension was diagnosed. Among studied
patients 41 had chronic complications of diabetes including
nephropathy in 15 patients, retinopathy in 21, neuropathy
in 29, and diabetic foot in 6 patients. Exclusion criteria
included the fifth stage of chronic kidney disease (GFR
< 15mL/min/1.73m2), inflammatory diseases, cancer, and
systemic diseases.
The control group was composed of 79 healthy subjects
matched according to age (mean 55.2±11; range 30–85 years)
and sex with the studied patients (Table 1).
Healthy subjects were recruited from the individuals who
went through regular medical check-up in the Department
of Diagnostics, University Hospital, Krakow, Poland. They
were selected among individuals with no history of cancer
and systemic diseases, healthy at the time of study, and whose
laboratory findings did not show inflammatory disease,
prediabetes, or diabetes.
Participation required informed consent signed by all
subjects enrolled both into the studied and into the control
group. The study had the approval of Jagiellonian University
Bioethics Commission number KBET/139/09/.
Blood samples for the study purposes were collected
using S-Monovette-serum and S-Monovette-EDTA tubes
(SARSTEDT AG&Co, Nümbrecht, Germany). Routine lab-
oratory tests including fasting glucose, lipid profile, gamma-
glutamyltransferase activity, and creatinine and uric acid
concentrations were performed in serum. HbA1c levels were
measured in whole blood.
The K
2
-EDTA blood samples were used for measure-
ments of selected antioxidant defense markers in plasma (the
ferric reducing ability of plasma (FRAP), glutathione perox-
idase (GPx), and glutathione reductase (GR) activity) and in
hemolysate (glutathione peroxidase (GPx) and glutathione
reductase (GR) activity and reduced glutathione concentra-
tion (GSH)). These blood samples were centrifuged for 10
minutes at 3000×g and the obtained plasma was separated,
aliquoted to microtubes, and stored frozen at −80∘C from
1 to 12 months until testing. Remaining erythrocytes were
separated from plasma, washed three times with isotonic
saline, and hemolyzed by a fourfold dilution with deionized
water. The obtained erythrocytes suspension was frozen
and stored overnight at −80∘C. Then hemolysate samples
were thawed and centrifuged at 3000×g for 10 minutes to
remove cell debris.The hemolysate samples were aliquoted to
microtubes and stored frozen at−80∘C for 1–12months before
use.
Hemoglobin concentration in hemolysate was measured
using the cyanmethemoglobin method [7]. After mixing
of hemolysate samples with diluted potassium ferricyanide
and potassium cyanide solution at a slightly alkaline pH
to form the stable cyanmethemoglobin, the absorbance was
measured at 540 nm using microplate EL-800 reader (BioTek
Instruments, Inc., USA). Hemolysate reduced glutathione
concentration was determined using the method described
by Beutler et al. employing 5,5󸀠-dithiobis(nitrobezoic) acid
forming with glutathione thiol groups colored adduct, with
spectrophotometric measurement at 412 nm [8]. Glutathione
peroxidase activity was measured in plasma and hemolysate
based on the decrease of NADPH absorbance at 340 nm
according to the method of Paglia and Valentine [9]. Simi-
larly, glutathione reductase activity was measured in plasma
and hemolysate using the method based on the reduction
of glutathione (GSSG) in the presence of NADPH, which
is oxidized to NADP+ [10]. Total antioxidant capacity was
measured as the ferric reducing ability of plasma (FRAP). In
this method ferric-tripyridyltriazine (Fe3+-TPTZ) complex
is reduced to the ferrous (Fe2+) form at low pH by the
plasma antioxidants. Reduced Fe2+-TPTZ takes on an intense
blue color, with the peak absorbance at 593 nm [11]. All
spectrophotometric measurements for the determination of
glutathione peroxidase and glutathione reductase activity and
the concentration of reduced glutathione were performed on
the MaxMat PL analyzer (Maxmat SA, Montpellier, France).
Statistics.Normality of distribution of obtained variables was
checked using the Shapiro Wilk test. Data are expressed as
mean ± SD, median and interquartile range, or percentage
of frequency, as appropriate. Relationships between paired
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Table 2: Comparison of antioxidant defense markers in patients with type 2 diabetes and controls.
Parameter Type 2 diabetes Control group 𝑝
FRAP [mmol/L] 0.97 ± 0.21 0.84 ± 0.16 <0.001
GPxplasma [U/L] 235.7 (93.2–359.9) 644.5 (466.0–798.8) <0.001
GPxhemolysate [U/gHb] 43.8 ± 21.5 55.4 ± 25.9 0.002
GRplasma [U/L] 74.5 ± 21.3 43.7 ± 13.5 <0.001
GRhemolysate [U/gHb] 33.0 (26.9–38.5) 22.62 (16.2–29.1) <0.001
GSH [𝜇mol/L] 0.87 (0.46–2.23) 0.92 (0.56–1.20) 0.117
Uric acid [𝜇mol/L] 364.3 ± 117.9 293.5 ± 85.7 <0.001
GGT [U/L] 23.5 (11.5–37.5) 10.5 (7.0–17.0) <0.001
CRP [mg/dL] 1.95 (0.85–5.72) 0.87 (0.46–2.23) <0.001
Data are expressed as mean ± SD and median and interquartile range.
parameters (continuous variables) were analyzed by Pear-
son product moment correlation coefficient. Variables with
positively skewed distribution were log transformed before
the correlation analysis. Differences between groups were
assessed by 𝑡-test for variables with positively skewed dis-
tribution and Mann-Whitney 𝑈 test for nonparametric vari-
ables. 𝑝 values less than 0.05 were taken as statistically
significant. All analyses were performed using a standard
statistical package Statistica 9.0 (StatSoft Inc.) and Microsoft
Office Excel 2007 spreadsheet (Microsoft Corporation).
3. Results
Thecharacteristics of the studied groups are shown in Table 1.
The studied group was characterized by hyperglycemia and
elevated glycated hemoglobin. Mean values of lipid profile
parameters did not fit treatment goals recommended by
diabetes associations including the Polish Diabetes Society
[12]. Mean BMI value was elevated and 55% of patients were
obese (BMI > 30 kg/m2).
The results of antioxidant defensemarkers measurements
in patients with diabetes and controls are shown in Table 2.
In subjects with type 2 diabetes significantly lower
levels of glutathione peroxidase and higher levels of glu-
tathione reductase both in plasma and hemolysate were
found.The trend towards decreased hemolysate reduced glu-
tathione concentrations in the group with diabetes compared
with controls (0.87 (0.46–2.23) 𝜇mol/L versus 0.92 (0.56–
1.20)𝜇mol/L) was observed.
Total antioxidant capacity of plasma assessed by the
FRAP, serumuric acid, andGGT, also involved in antioxidant
defense, were significantly higher in patients with diabetes
(Table 2). Plasma uric acid concentration was significantly
correlated with FRAP both in patients and in the control
group (Figures 1 and 2).
Fasting serum glucose correlated with glutathione per-
oxidase in plasma (𝑟 = −0.2816, 𝑝 < 0.001), glutathione
reductase in plasma and hemolysate (𝑟 = −0.2816, 𝑝 < 0.001;
𝑟 = 0.6010, 𝑝 < 0.001), FRAP (𝑟 = 0.3816, 𝑝 < 0.001),
and GGT (𝑟 = 0.4565, 𝑝 < 0.001). Moreover correlation
between GGT and HbA1c (𝑟 = 0.4179, 𝑝 < 0.001) was found
in diabetic patients.
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Figure 1: Correlation between FRAP and uric acid in people with
type 2 diabetes (𝑟 = 0.963; 𝑝 ≤ 0.001).
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Figure 2: Correlation between FRAP and uric acid levels in the
control group (𝑟 = 0.948; 𝑝 ≤ 0.001).
In patients with chronic diabetes complications (at least
one) no significant differences in antioxidant defensemarkers
as compared to those without complications were found
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Table 3: Comparison of selected clinical and biochemical parameters in patients with and without chronic diabetes complications.
Parameter Complications (𝑁 = 42) No complications (𝑁 = 38) 𝑝
Age [years] 60.9 ± 9.0 57.9 ± 13.9 0.009
BMI 30.92 ± 5.24 32.22 ± 6.22 0.315
Diabetes duration [years] 10 (7–16) 5 (1–9) <0.001
Mean daily glucose [mmol/L] 6.3 ± 1.0 6.3 ± 1.1 0.651
HbA1c [mmol/mol] 69.4 (58.5–74.9) 77.1 (51.9–92.4) 0.372
[%] 8.5 (7.5–9.0) 9.2 (6.9–10.6)
Creatinine [𝜇mol/L] 66.4 (59.4–76.0) 67.8 (56.1–83.0) 0.891
FRAP [mmol/L] 1.00 ± 0.22 0.94 ± 0.20 0.512
GPxplasma [U/L] 234.5 (89.2–60.5) 236.9 (98.4–59.3) 0.950
GPxhemolysate [U/gHg] 43.1 ± 22.0 44.6 ± 21.1 0.819
GRplasma [U/L] 73.1 ± 18.2 75.5 ± 24.5 0.063
GRhemolysate [U/gHg] 33.1 (27.1–38.6) 32.8 (26.7–37.9) 0.969
Glutatione [𝜇mol/L] 0.88 (0.53–1.18) 0.94 (0.71–1.21) 0.402
Uric acid [𝜇mol/L] 381.0 ± 131.0 345.2 ± 71.4 0.170
GGT [U/L] 22.5 (12–38) 25.5 (10.0–34.0) 0.711
CRP [mg/L] 1.7 (0.5–4.4) 2.7 (1.1–10.0) 0.117
Data are expressed as mean ± SD, median and interquartile range, or percentage of frequency [%], as appropriate.
(Table 3).However, for uric acid correlationwith albuminuria
was found (𝑟 = 0.46, 𝑝 = 0.02).
The relationship between metabolic syndrome features
present in studied patients and antioxidant defense markers
was also evaluated. No significant differences in these mark-
ers levels between obese (BMI > 30 kg/m2) and nonobese
patients with diabetes were found except for the FRAP and
uric acid concentrations significantly higher in obese (FRAP:
1.03 ± 0.2mmol/L versus 0.89 ± 0.18mmol/L; 𝑝 = 0.002;
UA: 6.7 ± 2.0 𝜇mol/L versus 5.4 ± 1.7 𝜇mol/L, 𝑝 = 0.003)
and significantly correlated with BMI (FRAP: 𝑟 = 0.593,
𝑝 < 0.001; UA: 𝑟 = 0.415, 𝑝 < 0.001). Hypertensive patients
with diabetes had significantly higher glutathione reductase
activity in hemolysate as compared to those without hyper-
tension (38.6U/L versus 32.7U/L, 𝑝 = 0.03).
4. Discussion
Diabetes is a state of increased oxidative stress, which is
one of the mechanisms leading to development of chronic
diabetes complications [1].While it is believed that diabetes is
associated with an increased production of ROS, the reports
of the antioxidant defense in diabetes are contradictory [5,
6]. In this study markers of antioxidant defense in patients
with type 2 diabetes were evaluated. The study included
a heterogeneous group of patients with type 2 diabetes—
with and without chronic complications, and a part of
patients had obesity, hypertension, and other features of the
metabolic syndrome. Results obtained in this study showed
that patients with diabetes had significantly higher antioxi-
dant defense activity reflected by FRAP, glutathione reductase
and gamma-glutamyltransferase activity, and uric acid levels.
Glutathione peroxidase activity measurements in plasma and
hemolysate yielded significantly lower results in the patients
group (Table 2). Similarly, an inverse relationship between
glutathione peroxidase and glutathione reductase in patients
with type 2 diabetes and the control group was observed
by Kumawat et al. [13]. In another study decreased activity
of both glutathione peroxidase and glutathione reductase in
type 2 diabetes was found [14].
The low activity of GPx could be directly explained by the
low content of GSH found in patients with type 2 diabetes,
since GSH is a substrate and cofactor of GPx. Enzyme
inactivation could also contribute to low GPx activity. GPx
is a relatively stable enzyme, but it may be inactivated under
conditions of severe oxidative stress. Inactivation of this
enzyme may occur through glycation governed by prevailing
glucose concentration [15]. Increased activity of GR may
be a compensatory response to oxidative stress. Changes
in glutathione peroxidase and glutathione reductase activity
found in this study can be considered an adaptation of
antioxidant defense against increased production of ROS.
However, this adaptation seems to be ineffective. Reduced
GSH level in red blood cells reflects generalized decrease in
intracellular content of this compound. The obtained results
showed that patients with type 2 diabetes had lower GSH
content in erythrocytes than observed in the control group.
However, this difference was not statistically significant. The
trend found in our results is consistent with the report
of Aaseth and colleagues, who found reduced levels of
glutathione in erythrocytes of subjects with obesity and
poorly controlled type 2 diabetes [16]. Similarly, decrease
in intracellular glutathione levels in patients with type 2
diabetes was reported by Livingstone in his recent review [17].
These results indicate that patients with type 2 diabetes have
lower concentration of intracellular GSH,which increases the
susceptibility of cells to the damaging effects of ROS.
There were no significant differences in oxidative defense
markers between patients with and without chronic diabetes
complications.
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Plasma glutathione reductase, plasma glutathione perox-
idase, FRAP, and GGT were associated with fasting glucose
concentration, which indicated the association of higher level
of antioxidant defense with hyperglycemia and subsequent
ROS production. This activation of antioxidant defense
seems to be associated with short-term glycemia fluctuations,
because no relationship between antioxidant defensemarkers
and HbA1c was found.
Metabolic syndrome includes risk factors for develop-
ment of type 2 diabetes—hypertension and atherogenic
dyslipidemia (elevated triglycerides and decreased HDL
cholesterol concentrations). In obese patients serum uric
acid levels were significantly higher as compared with those
without obesity. We also observed significant positive cor-
relation between BMI and serum uric acid concentrations
and negative with plasma glutathione peroxidase activity.
Decreased glutathione peroxidase activity associated with
increased BMI is reported as a feature of oxidative stress in
obese individuals [18].
In the whole studied group significant correlation
between uric acid concentration and plasma total antioxidant
capacity both in patients (𝑟 = 0.963) and in the control group
(𝑟 = 0.948) was found. This observation confirms the well-
known relationship between the level of antioxidant capacity
measured as FRAP and plasma uric acid [11]. Moreover,
serum uric acid concentrations correlated significantly with
HDL cholesterol (negatively) and triglycerides (positively)
levels. Similarly, increased levels of uric acid were reported
by Chen et al. to be associated with abnormal levels of
HDL [19]. Increase in uric acid concentrations is a well-
known abnormality observed in metabolic syndrome. The
underlying mechanisms are not fully explained. Recently it
was demonstrated that leptin may influence hyperuricemia
associated with obesity. Uric acid is considered a risk factor
for diabetes complications. The study by Hovind et al.
showed that uric acid is an independent risk factor for the
development of diabetic nephropathy in type 1 diabetes.
Moreover, in this study correlation between serum uric
acid and albuminuria was found [20]. Similar results were
reported for patients with type 2 diabetes [21]. Significant
correlation between serum uric acid and albuminuria was
demonstrated in our study but the limitation is the small
number of albuminuric patients studied. Regardless of these
relationships uric acid remains an important component of
antioxidant defense.
Another enzyme involved in glutathionemetabolism and
the overall antioxidant defense system is GGT responsible
for glutathione uptake from the extracellular fluid into the
cells to maintain its constant level. Recently the relationship
between plasma GGT activity and obesity with the risk for
type 2 diabetes was reported [22]. In our study themeanGGT
activity was significantly higher in diabetes individuals but
without significant correlation with BMI.
Monitoring antioxidant defenses may also be important
in clinical practice. Since the increased antioxidant defense
may alleviate oxidative stress, supplementation with antiox-
idants has been considered an attractive potential therapy.
This approach has been evaluated in numerous clinical trials
assessing the effect of antioxidants supplementation on the
risk for diabetes, glycemic control, and the development of
chronic complications. However, the results of these studies
are contradictory and do not allow us to draw consistent con-
clusion [23–29]. Nevertheless, our results indicating insuffi-
cient activation of antioxidant defense in type 2 diabetes may
argue for the usefulness of such supplementation.
In summary, results obtained in this study show that
some components of antioxidant defense such as glutathione
reductase, uric acid, andGGTare increased in type 2 diabetes.
However, this system seems to be ineffective as reflected
by the trend toward decreased reduced glutathione content
in erythrocytes. Although increased, the whole system of
antioxidant defense cannot compensate for an enhanced
production of ROS in diabetes, which results in oxidative
stress. These data may indicate the usefulness of therapies
enhancing antioxidant defense.
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